


U.S. & E.U. Differ on Filgotinib for RA

Abx464 Enters Phase 2 Clinical Trials for RA in Europe

Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe

Delayed Care: Research Paints Complex Picture of Treatment Delays

EU Approves Marketing for Ixekizumab in Adults with PsA

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?
European Group Offers Guidance on Managing Juvenile Dermatomyositis
Europe Launches New Fast Approval Scheme for Promising Drugs
